Millennium Management’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.45M | Buy |
1,410,845
+7,466
| +0.5% | +$12.3K | ﹤0.01% | 3674 |
|
|
2025
Q4 | $2.44M | Sell |
1,403,379
-569,139
| -29% | -$1.25M | ﹤0.01% | 3765 |
|
|
2025
Q3 | $4.62M | Buy |
1,972,518
+1,625,653
| +469% | +$3.11M | ﹤0.01% | 3224 |
|
|
2025
Q2 | $706K | Buy |
+346,865
| New | +$665K | ﹤0.01% | 4663 |
|
|
2024
Q4 | – | Sell |
-30,222
| Closed | -$175K | – | 6188 |
|
|
2024
Q3 | $175K | Buy |
30,222
+4,450
| +17% | +$36.7K | ﹤0.01% | 5483 |
|
|
2024
Q2 | $208K | Sell |
25,772
-242,030
| -90% | -$2.55M | ﹤0.01% | 5118 |
|
|
2024
Q1 | $3.72M | Buy |
267,802
+232,709
| +663% | +$2.01M | ﹤0.01% | 3175 |
|
|
2023
Q4 | $215K | Sell |
35,093
-346,445
| -91% | -$1.71M | ﹤0.01% | 5145 |
|
|
2023
Q3 | $1.78M | Sell |
381,538
-63,483
| -14% | -$351K | ﹤0.01% | 3668 |
|
|
2023
Q2 | $2.38M | Buy |
+445,021
| New | +$3.59M | ﹤0.01% | 3321 |
|
|
2023
Q1 | – | Sell |
-359,696
| Closed | -$6.73M | – | 6591 |
|
|
2022
Q4 | $6.73M | Buy |
359,696
+184,843
| +106% | +$4.19M | ﹤0.01% | 2539 |
|
|
2022
Q3 | $3.62M | Buy |
+174,853
| New | +$4.48M | ﹤0.01% | 3196 |
|
|
2021
Q4 | – | Sell |
-1,276
| Closed | -$110K | – | 7083 |
|
|
2021
Q3 | $110K | Buy |
+1,276
| New | +$128K | ﹤0.01% | 6396 |
|
|
2021
Q2 | – | Sell |
-10,642
| Closed | -$1.02M | – | 6768 |
|
|
2021
Q1 | $1.19M | Sell |
10,642
-7,618
| -42% | -$1M | ﹤0.01% | 4046 |
|
|
2020
Q4 | $1.94M | Buy |
18,260
+14,866
| +438% | +$1.98M | ﹤0.01% | 3263 |
|
|
2020
Q3 | $472 | Sell |
3,394
-6,151
| -64% | -$1.28M | ﹤0.01% | 3611 |
|
|
2020
Q2 | $3.09M | Sell |
9,545
-131,427
| -93% | -$21.1M | ﹤0.01% | 2190 |
|
|
2020
Q1 | $12.6M | Buy |
140,972
+139,576
| +9,998% | +$8.61M | 0.03% | 700 |
|
|
2019
Q4 | $55K | Buy |
+1,396
| New | +$42K | ﹤0.01% | 4088 |
|
|
2019
Q1 | – | Sell |
-2,914
| Closed | -$140K | – | 4125 |
|
|
2018
Q4 | $140K | Sell |
2,914
-2,556
| -47% | -$155K | ﹤0.01% | 3491 |
|
|
2018
Q3 | $365K | Sell |
5,470
-5,343
| -49% | -$298K | ﹤0.01% | 3390 |
|
|
2018
Q2 | $509K | Buy |
10,813
+6,813
| +170% | +$376K | ﹤0.01% | 3156 |
|
|
2018
Q1 | $226K | Sell |
4,000
-365
| -8% | -$19.8K | ﹤0.01% | 3335 |
|
|
2017
Q4 | $216K | Sell |
4,365
-94,265
| -96% | -$5.84M | ﹤0.01% | 3498 |
|
|
2017
Q3 | $7.5M | Buy |
98,630
+28,358
| +40% | +$2.11M | 0.01% | 1437 |
|
|
2017
Q2 | $6.61M | Buy |
70,272
+66,981
| +2,035% | +$5.73M | 0.01% | 1312 |
|
|
2017
Q1 | $261K | Sell |
3,291
-13,310
| -80% | -$1.06M | ﹤0.01% | 3103 |
|
|
2016
Q4 | $1.38M | Buy |
+16,601
| New | +$1.5M | ﹤0.01% | 2073 |
|
|
2016
Q3 | – | Sell |
-1,176
| Closed | -$130K | – | 3418 |
|
|
2016
Q2 | $130K | Sell |
1,176
-6,724
| -85% | -$817K | ﹤0.01% | 2982 |
|
|
2016
Q1 | $826K | Sell |
7,900
-50,229
| -86% | -$3.88M | ﹤0.01% | 2283 |
|
|
2015
Q4 | $4.69M | Buy |
58,129
+29,307
| +102% | +$2.33M | 0.01% | 1405 |
|
|
2015
Q3 | $2M | Buy |
28,822
+18,042
| +167% | +$1.57M | ﹤0.01% | 1902 |
|
|
2015
Q2 | $1.06M | Buy |
10,780
+8,182
| +315% | +$874K | ﹤0.01% | 2256 |
|
|
2015
Q1 | $254K | Sell |
2,598
-1,957
| -43% | -$190K | ﹤0.01% | 3152 |
|
|
2014
Q4 | $502K | Buy |
+4,555
| New | +$557K | ﹤0.01% | 2979 |
|
|
2014
Q3 | – | Sell |
-5,127
| Closed | -$665K | – | 3832 |
|
|
2014
Q2 | $665K | Buy |
5,127
+4,471
| +682% | +$528K | ﹤0.01% | 2422 |
|
|
2014
Q1 | $105K | Buy |
+656
| New | +$94.2K | ﹤0.01% | 3289 |
|
Other funds holding INO
VCM
BCM
ACM
EP
Millennium Management's INO Position: Q1 2026 in Review
Millennium Management increased its Inovio Pharmaceuticals (INO) stake by 0.53% in Q1 2026, buying an estimated $12.3K and bringing the position to 1,410,845 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #3674.
Millennium Management first reported a position in INO in Q1 2014 and has held it in 37 quarters since. The position peaked at $12.6M in Q1 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.
- Millennium Management held 1,410,845 shares of Inovio Pharmaceuticals worth $2.45M as of Q1 2026.
- Millennium Management bought 7,466 Inovio Pharmaceuticals shares in Q1 2026, an estimated $12.3K.
- Inovio Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3674 holding.
- Millennium Management first reported a position in Inovio Pharmaceuticals in Q1 2014 and has held it in 37 quarters since.
- Millennium Management's Inovio Pharmaceuticals position peaked at $12.6M in Q1 2020.
- 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.